NasdaqGM - Nasdaq Real Time Price USD

Intellia Therapeutics, Inc. (NTLA)

8.32

-0.23

(-2.69%)

At close: May 13 at 4:00:01 PM EDT

8.39

+0.07

+(0.84%)

After hours: May 13 at 7:58:18 PM EDT

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report

Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) just released its latest quarterly results and things are looking bullish...

Simply Wall St. 2 days ago

NTLA
-2.69%
News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts

Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) shareholders will have a reason to smile today, with the analysts making...

Simply Wall St. 3 days ago

NTLA
-2.69%
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.

Zacks 4 days ago

NTLA
-2.69%
Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

Intellia Therapeutics Inc (NTLA) showcases clinical progress and financial strategy despite a drop in collaboration revenue and cash reserves.

GuruFocus.com 5 days ago

NTLA
-2.69%
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 12.70% and 14.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 days ago

NTLA
-2.69%
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion

GlobeNewswire 5 days ago

NTLA
-2.69%
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on May 1, 2025, it awarded an inducement grant to eight new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grant consisted of time-based restricted stock units (“RSUs”) for 69,600 shares of Intellia’s common stock, wit

GlobeNewswire 7 days ago

NTLA
-2.69%
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 20% and 8.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 days ago

NTLA
-2.69%
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 8 days ago

OBIO

NTLA
-2.69%
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 12 days ago

NTLA
-2.69%

KRYS
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Zacks 12 days ago

NTLA
-2.69%
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All par

GlobeNewswire 12 days ago

NTLA
-2.69%
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The popular growth investor keeps adding to some of her favorite stocks.

Motley Fool 13 days ago

AMD

SHOP

NTLA
-2.69%
Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 392.8% in Intellia Therapeutics (NTLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 14 days ago

NTLA
-2.69%
Trump’s FDA Sends a Bullish Signal to Biotech

A vow by the agency’s new commissioner, Marty Makary, to support innovation might ease fears stoked by Health and Human Services Secretary Robert F. Kennedy Jr.

The Wall Street Journal 21 days ago

MFG

MZHOF

RGNX
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Investor's Business Daily 22 days ago

DYN

RNA

SRPT
Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

Insider Monkey last month

NTLA
-2.69%
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

The trial is structured to assess the safety and efficacy of the therapy in approximately 50 ATTRv-PN subjects.

Clinical Trials Arena last month

NTLA
-2.69%
IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

If preclinical findings were translated into clinic, they could shorten CAR-T generation lead time to one day.

Pharmaceutical Technology last month

NTLA
-2.69%
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). “We are pleased to have dosed the first patient with a treatment that has such stro

GlobeNewswire last month

NTLA
-2.69%

Performance Overview

Return	NTLA	S&P 500 (^GSPC)
YTD	-28.64%	+0.08%
1-Year	-67.27%	+12.74%
3-Year	-82.88%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Intellia Therapeutics, Inc. (NTLA)

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report

News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

Trump’s FDA Sends a Bullish Signal to Biotech

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Performance Overview